Rhythm Pharma Stock Drops as Obesity Drug Trial Misses Goal

Rhythm Pharma Shares Decline on Trial Results

Rhythm Pharmaceuticals Inc (NASDAQ:RYTM) shares fell approximately 5% in after-hours trading following the announcement that its Phase 3 trial for an obesity drug failed to meet its primary endpoint.

Trial Overview and Findings

The study for the drug, Emanate, was designed to treat obesity in patients with specific rare genetic conditions. The primary objective was to achieve a statistically significant reduction in body mass index, or BMI. The company confirmed that this goal was not met across the broader patient population in the trial.

Market Impact and Future Outlook

The market reacted swiftly to the news, with the stock price dropping to $85.99 in aftermarket trade. Despite the setback, Rhythm Pharmaceuticals reported that a subsequent analysis revealed positive outcomes in specific genetic subgroups. The drug demonstrated statistically significant BMI reductions in patients with POMC/PCSK1 and SRC1 genetic disorders.

Summary and Next Steps

While the trial did not achieve its main objective, the promising data from specific patient cohorts offers a potential path forward. Rhythm Pharmaceuticals announced its intention to pursue further testing focused specifically on these genetic groups to validate the drug's efficacy.

FAQ

Q: Why did Rhythm Pharmaceuticals' stock price fall?
A: The stock price fell because the company's Phase 3 clinical trial for its obesity drug, Emanate, did not meet its primary goal of significant BMI reduction in the overall study group.

Q: Was the drug trial a complete failure?
A: Not entirely. A later analysis showed the drug was effective for patients with specific genetic disorders, namely POMC/PCSK1 and SRC1. The company plans further research on these groups.

Source: Investing.com